Status:
UNKNOWN
Noninvasive Spinal Neuromodulation Enables Locomotor Recovery in Individuals With Cerebral Palsy
Lead Sponsor:
SpineX Inc.
Conditions:
Cerebral Palsy
Eligibility:
All Genders
2-75 years
Phase:
PHASE1
Brief Summary
Assessing the effects of noninvasive spinal cord neuromodulation on improving function in individuals with cerebral palsy
Eligibility Criteria
Inclusion
- 1\) individuals above the age of 2 years of age and 2) diagnosed with cerebral palsy (CP). The exclusion criteria included 1) children with selective dorsal root rhizotomy, 2) intramuscular Botox injection in the preceding 12 months, 3) current antispastic medications 4) unhealed fractures or contractures that would prevent them from performing functional tasks and 5) tendon lengthening surgeries.
Exclusion
- Intramuscular Botox injection in the past 12 months
Key Trial Info
Start Date :
May 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04882592
Start Date
May 15 2021
End Date
December 1 2024
Last Update
April 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
SpineX
Los Angeles, California, United States, 90064